Potassium channel blocker 4‐aminopyridine is effective in interictal cerebellar symptoms in episodic ataxia type 2 — A video case report
Identifieur interne : 000D56 ( Istex/Corpus ); précédent : 000D55; suivant : 000D57Potassium channel blocker 4‐aminopyridine is effective in interictal cerebellar symptoms in episodic ataxia type 2 — A video case report
Auteurs : Matthias Löhle ; Wiebke Schrempf ; Martin Wolz ; Heinz Reichmann ; Alexander StorchSource :
- Movement Disorders [ 0885-3185 ] ; 2008-07-15.
English descriptors
Abstract
Episodic ataxia type 2 (EA2) is an autosomal‐dominant hereditary disorder clinically characterized by recurrent attacks of vertigo, imbalance and ataxia. Studies have shown that 4‐aminopyridine (4‐AP) is capable to prevent these attacks. However, there are no reports whether 4‐AP is able to attenuate interictal cerebellar ataxia. Using the scale for assessment and rating of ataxia (SARA), we examined the efficacy of 4‐AP on interictal ataxia in a 63‐year‐old female patient who suffered from EA2 since the age of 57. EA2 was diagnosed based on clinical criteria and not genetically proven. When treatment with 4‐AP was paused the patient was suffering from marked gait and stance ataxia. After re‐initiation of treatment with 5 mg 4‐AP t.i.d., there was pronounced improvement in gait and stance ataxia. Within 24 hours SARA score lowered from 8.5 to 4.5 points. We conclude that 4‐AP may be beneficial for interictal cerebellar ataxia in late onset EA2. © 2008 Movement Disorder Society
Url:
DOI: 10.1002/mds.22071
Links to Exploration step
ISTEX:5A29F579CCD897BEF9D98809889B96228D2F0AFALe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Potassium channel blocker 4‐aminopyridine is effective in interictal cerebellar symptoms in episodic ataxia type 2 — A video case report</title><author><name sortKey="Lohle, Matthias" sort="Lohle, Matthias" uniqKey="Lohle M" first="Matthias" last="Löhle">Matthias Löhle</name><affiliation><mods:affiliation>Department of Neurology, Technical University of Dresden, Dresden, Germany</mods:affiliation></affiliation></author><author><name sortKey="Schrempf, Wiebke" sort="Schrempf, Wiebke" uniqKey="Schrempf W" first="Wiebke" last="Schrempf">Wiebke Schrempf</name><affiliation><mods:affiliation>Department of Neurology, Technical University of Dresden, Dresden, Germany</mods:affiliation></affiliation></author><author><name sortKey="Wolz, Martin" sort="Wolz, Martin" uniqKey="Wolz M" first="Martin" last="Wolz">Martin Wolz</name><affiliation><mods:affiliation>Department of Neurology, Technical University of Dresden, Dresden, Germany</mods:affiliation></affiliation></author><author><name sortKey="Reichmann, Heinz" sort="Reichmann, Heinz" uniqKey="Reichmann H" first="Heinz" last="Reichmann">Heinz Reichmann</name><affiliation><mods:affiliation>Department of Neurology, Technical University of Dresden, Dresden, Germany</mods:affiliation></affiliation></author><author><name sortKey="Storch, Alexander" sort="Storch, Alexander" uniqKey="Storch A" first="Alexander" last="Storch">Alexander Storch</name><affiliation><mods:affiliation>Department of Neurology, Technical University of Dresden, Dresden, Germany</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:5A29F579CCD897BEF9D98809889B96228D2F0AFA</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/mds.22071</idno><idno type="url">https://api.istex.fr/document/5A29F579CCD897BEF9D98809889B96228D2F0AFA/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000D56</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Potassium channel blocker 4‐aminopyridine is effective in interictal cerebellar symptoms in episodic ataxia type 2 — A video case report</title><author><name sortKey="Lohle, Matthias" sort="Lohle, Matthias" uniqKey="Lohle M" first="Matthias" last="Löhle">Matthias Löhle</name><affiliation><mods:affiliation>Department of Neurology, Technical University of Dresden, Dresden, Germany</mods:affiliation></affiliation></author><author><name sortKey="Schrempf, Wiebke" sort="Schrempf, Wiebke" uniqKey="Schrempf W" first="Wiebke" last="Schrempf">Wiebke Schrempf</name><affiliation><mods:affiliation>Department of Neurology, Technical University of Dresden, Dresden, Germany</mods:affiliation></affiliation></author><author><name sortKey="Wolz, Martin" sort="Wolz, Martin" uniqKey="Wolz M" first="Martin" last="Wolz">Martin Wolz</name><affiliation><mods:affiliation>Department of Neurology, Technical University of Dresden, Dresden, Germany</mods:affiliation></affiliation></author><author><name sortKey="Reichmann, Heinz" sort="Reichmann, Heinz" uniqKey="Reichmann H" first="Heinz" last="Reichmann">Heinz Reichmann</name><affiliation><mods:affiliation>Department of Neurology, Technical University of Dresden, Dresden, Germany</mods:affiliation></affiliation></author><author><name sortKey="Storch, Alexander" sort="Storch, Alexander" uniqKey="Storch A" first="Alexander" last="Storch">Alexander Storch</name><affiliation><mods:affiliation>Department of Neurology, Technical University of Dresden, Dresden, Germany</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-07-15">2008-07-15</date><biblScope unit="vol">23</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1314">1314</biblScope><biblScope unit="page" to="1316">1316</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">5A29F579CCD897BEF9D98809889B96228D2F0AFA</idno><idno type="DOI">10.1002/mds.22071</idno><idno type="ArticleID">MDS22071</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>4‐aminopyridine</term><term>SARA</term><term>episodic ataxia type 2</term><term>interictal ataxia</term><term>video case report</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Episodic ataxia type 2 (EA2) is an autosomal‐dominant hereditary disorder clinically characterized by recurrent attacks of vertigo, imbalance and ataxia. Studies have shown that 4‐aminopyridine (4‐AP) is capable to prevent these attacks. However, there are no reports whether 4‐AP is able to attenuate interictal cerebellar ataxia. Using the scale for assessment and rating of ataxia (SARA), we examined the efficacy of 4‐AP on interictal ataxia in a 63‐year‐old female patient who suffered from EA2 since the age of 57. EA2 was diagnosed based on clinical criteria and not genetically proven. When treatment with 4‐AP was paused the patient was suffering from marked gait and stance ataxia. After re‐initiation of treatment with 5 mg 4‐AP t.i.d., there was pronounced improvement in gait and stance ataxia. Within 24 hours SARA score lowered from 8.5 to 4.5 points. We conclude that 4‐AP may be beneficial for interictal cerebellar ataxia in late onset EA2. © 2008 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Matthias Löhle MD</name><affiliations><json:string>Department of Neurology, Technical University of Dresden, Dresden, Germany</json:string></affiliations></json:item><json:item><name>Wiebke Schrempf MD</name><affiliations><json:string>Department of Neurology, Technical University of Dresden, Dresden, Germany</json:string></affiliations></json:item><json:item><name>Martin Wolz MD</name><affiliations><json:string>Department of Neurology, Technical University of Dresden, Dresden, Germany</json:string></affiliations></json:item><json:item><name>Heinz Reichmann MD, PhD</name><affiliations><json:string>Department of Neurology, Technical University of Dresden, Dresden, Germany</json:string></affiliations></json:item><json:item><name>Alexander Storch MD</name><affiliations><json:string>Department of Neurology, Technical University of Dresden, Dresden, Germany</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>episodic ataxia type 2</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>4‐aminopyridine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>interictal ataxia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>SARA</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>video case report</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Episodic ataxia type 2 (EA2) is an autosomal‐dominant hereditary disorder clinically characterized by recurrent attacks of vertigo, imbalance and ataxia. Studies have shown that 4‐aminopyridine (4‐AP) is capable to prevent these attacks. However, there are no reports whether 4‐AP is able to attenuate interictal cerebellar ataxia. Using the scale for assessment and rating of ataxia (SARA), we examined the efficacy of 4‐AP on interictal ataxia in a 63‐year‐old female patient who suffered from EA2 since the age of 57. EA2 was diagnosed based on clinical criteria and not genetically proven. When treatment with 4‐AP was paused the patient was suffering from marked gait and stance ataxia. After re‐initiation of treatment with 5 mg 4‐AP t.i.d., there was pronounced improvement in gait and stance ataxia. Within 24 hours SARA score lowered from 8.5 to 4.5 points. We conclude that 4‐AP may be beneficial for interictal cerebellar ataxia in late onset EA2. © 2008 Movement Disorder Society</abstract><qualityIndicators><score>6.86</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>991</abstractCharCount><pdfWordCount>19984</pdfWordCount><pdfCharCount>133368</pdfCharCount><pdfPageCount>35</pdfPageCount><abstractWordCount>155</abstractWordCount></qualityIndicators><title>Potassium channel blocker 4‐aminopyridine is effective in interictal cerebellar symptoms in episodic ataxia type 2 — A video case report</title><genre><json:string>Serial article</json:string></genre><host><volume>23</volume><pages><total>4</total><last>1316</last><first>1314</first></pages><issn><json:string>0885-3185</json:string></issn><issue>9</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2008</publicationDate><copyrightDate>2008</copyrightDate><doi><json:string>10.1002/mds.22071</json:string></doi><id>5A29F579CCD897BEF9D98809889B96228D2F0AFA</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/5A29F579CCD897BEF9D98809889B96228D2F0AFA/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/5A29F579CCD897BEF9D98809889B96228D2F0AFA/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/5A29F579CCD897BEF9D98809889B96228D2F0AFA/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Potassium channel blocker 4‐aminopyridine is effective in interictal cerebellar symptoms in episodic ataxia type 2 — A video case report</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2008</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Potassium channel blocker 4‐aminopyridine is effective in interictal cerebellar symptoms in episodic ataxia type 2 — A video case report</title><author><persName><forename type="first">Matthias</forename><surname>Löhle</surname><roleName type="degree">MD</roleName></persName><note type="correspondence"><p>Correspondence: Klinik und Poliklinik für Neurologie, Fetscherstrasse 74, 01307 Dresden, Germany</p></note><affiliation>Department of Neurology, Technical University of Dresden, Dresden, Germany</affiliation></author><author><persName><forename type="first">Wiebke</forename><surname>Schrempf</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, Technical University of Dresden, Dresden, Germany</affiliation></author><author><persName><forename type="first">Martin</forename><surname>Wolz</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, Technical University of Dresden, Dresden, Germany</affiliation></author><author><persName><forename type="first">Heinz</forename><surname>Reichmann</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Department of Neurology, Technical University of Dresden, Dresden, Germany</affiliation></author><author><persName><forename type="first">Alexander</forename><surname>Storch</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, Technical University of Dresden, Dresden, Germany</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-07-15"></date><biblScope unit="vol">23</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1314">1314</biblScope><biblScope unit="page" to="1316">1316</biblScope></imprint></monogr><idno type="istex">5A29F579CCD897BEF9D98809889B96228D2F0AFA</idno><idno type="DOI">10.1002/mds.22071</idno><idno type="ArticleID">MDS22071</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2008</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Episodic ataxia type 2 (EA2) is an autosomal‐dominant hereditary disorder clinically characterized by recurrent attacks of vertigo, imbalance and ataxia. Studies have shown that 4‐aminopyridine (4‐AP) is capable to prevent these attacks. However, there are no reports whether 4‐AP is able to attenuate interictal cerebellar ataxia. Using the scale for assessment and rating of ataxia (SARA), we examined the efficacy of 4‐AP on interictal ataxia in a 63‐year‐old female patient who suffered from EA2 since the age of 57. EA2 was diagnosed based on clinical criteria and not genetically proven. When treatment with 4‐AP was paused the patient was suffering from marked gait and stance ataxia. After re‐initiation of treatment with 5 mg 4‐AP t.i.d., there was pronounced improvement in gait and stance ataxia. Within 24 hours SARA score lowered from 8.5 to 4.5 points. We conclude that 4‐AP may be beneficial for interictal cerebellar ataxia in late onset EA2. © 2008 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>episodic ataxia type 2</term></item><item><term>4‐aminopyridine</term></item><item><term>interictal ataxia</term></item><item><term>SARA</term></item><item><term>video case report</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2007-08-27">Received</change><change when="2008-03-12">Registration</change><change when="2008-07-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/5A29F579CCD897BEF9D98809889B96228D2F0AFA/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="90"><doi origin="wiley" registered="yes">10.1002/mds.v23:9</doi><numberingGroup><numbering type="journalVolume" number="23">23</numbering><numbering type="journalIssue">9</numbering></numberingGroup><coverDate startDate="2008-07-15">15 July 2008</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="220" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.22071</doi><idGroup><id type="unit" value="MDS22071"></id></idGroup><countGroup><count type="pageTotal" number="4"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2008 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2007-08-27"></event><event type="manuscriptRevised" date="2008-03-06"></event><event type="manuscriptAccepted" date="2008-03-12"></event><event type="firstOnline" date="2008-04-28"></event><event type="publishedOnlineFinalForm" date="2008-07-29"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2008-04-28"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText mathml2tex" date="2011-03-17"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1314</numbering><numbering type="pageLast">1316</numbering></numberingGroup><correspondenceTo>Klinik und Poliklinik für Neurologie, Fetscherstrasse 74, 01307 Dresden, Germany</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS22071.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="7"></count><count type="wordTotal" number="2091"></count></countGroup><titleGroup><title type="main" xml:lang="en">Potassium channel blocker 4‐aminopyridine is effective in interictal cerebellar symptoms in episodic ataxia type 2 — A video case report</title><title type="short" xml:lang="en">4‐Aminopyridine in Episodic Ataxia Type 2</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Matthias</givenNames><familyName>Löhle</familyName><degrees>MD</degrees></personName><contactDetails><email normalForm="matthias.loehle@neuro.med.tu-dresden.de">matthias.loehle@neuro.med.tu‐dresden.de</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Wiebke</givenNames><familyName>Schrempf</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Martin</givenNames><familyName>Wolz</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Heinz</givenNames><familyName>Reichmann</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Alexander</givenNames><familyName>Storch</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="DE" type="organization"><unparsedAffiliation>Department of Neurology, Technical University of Dresden, Dresden, Germany</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">episodic ataxia type 2</keyword><keyword xml:id="kwd2">4‐aminopyridine</keyword><keyword xml:id="kwd3">interictal ataxia</keyword><keyword xml:id="kwd4">SARA</keyword><keyword xml:id="kwd5">video case report</keyword></keywordGroup><supportingInformation><p> This article includes supplementary video clips, available online at <url href="http://www.interscience.wiley.com/jpages/0885-3185/suppmat"> http://www.interscience.wiley.com/jpages/0885‐3185/suppmat </url> . </p><supportingInfoItem><mediaResource alt="supporting information" href="urn-x:wiley:08853185:media:mds22071:mds22071-MDS22071"></mediaResource><caption>Please see article for description of video.</caption></supportingInfoItem></supportingInformation><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Episodic ataxia type 2 (EA2) is an autosomal‐dominant hereditary disorder clinically characterized by recurrent attacks of vertigo, imbalance and ataxia. Studies have shown that 4‐aminopyridine (4‐AP) is capable to prevent these attacks. However, there are no reports whether 4‐AP is able to attenuate interictal cerebellar ataxia. Using the scale for assessment and rating of ataxia (SARA), we examined the efficacy of 4‐AP on interictal ataxia in a 63‐year‐old female patient who suffered from EA2 since the age of 57. EA2 was diagnosed based on clinical criteria and not genetically proven. When treatment with 4‐AP was paused the patient was suffering from marked gait and stance ataxia. After re‐initiation of treatment with 5 mg 4‐AP t.i.d., there was pronounced improvement in gait and stance ataxia. Within 24 hours SARA score lowered from 8.5 to 4.5 points. We conclude that 4‐AP may be beneficial for interictal cerebellar ataxia in late onset EA2. © 2008 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Potassium channel blocker 4‐aminopyridine is effective in interictal cerebellar symptoms in episodic ataxia type 2 — A video case report</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>4‐Aminopyridine in Episodic Ataxia Type 2</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Potassium channel blocker 4‐aminopyridine is effective in interictal cerebellar symptoms in episodic ataxia type 2 — A video case report</title></titleInfo><name type="personal"><namePart type="given">Matthias</namePart><namePart type="family">Löhle</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Technical University of Dresden, Dresden, Germany</affiliation><description>Correspondence: Klinik und Poliklinik für Neurologie, Fetscherstrasse 74, 01307 Dresden, Germany</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Wiebke</namePart><namePart type="family">Schrempf</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Technical University of Dresden, Dresden, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Martin</namePart><namePart type="family">Wolz</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Technical University of Dresden, Dresden, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Heinz</namePart><namePart type="family">Reichmann</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, Technical University of Dresden, Dresden, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Alexander</namePart><namePart type="family">Storch</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Technical University of Dresden, Dresden, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2008-07-15</dateIssued><dateCaptured encoding="w3cdtf">2007-08-27</dateCaptured><dateValid encoding="w3cdtf">2008-03-12</dateValid><copyrightDate encoding="w3cdtf">2008</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">1</extent><extent unit="references">7</extent><extent unit="words">2091</extent></physicalDescription><abstract lang="en">Episodic ataxia type 2 (EA2) is an autosomal‐dominant hereditary disorder clinically characterized by recurrent attacks of vertigo, imbalance and ataxia. Studies have shown that 4‐aminopyridine (4‐AP) is capable to prevent these attacks. However, there are no reports whether 4‐AP is able to attenuate interictal cerebellar ataxia. Using the scale for assessment and rating of ataxia (SARA), we examined the efficacy of 4‐AP on interictal ataxia in a 63‐year‐old female patient who suffered from EA2 since the age of 57. EA2 was diagnosed based on clinical criteria and not genetically proven. When treatment with 4‐AP was paused the patient was suffering from marked gait and stance ataxia. After re‐initiation of treatment with 5 mg 4‐AP t.i.d., there was pronounced improvement in gait and stance ataxia. Within 24 hours SARA score lowered from 8.5 to 4.5 points. We conclude that 4‐AP may be beneficial for interictal cerebellar ataxia in late onset EA2. © 2008 Movement Disorder Society</abstract><subject lang="en"><genre>Keywords</genre><topic>episodic ataxia type 2</topic><topic>4‐aminopyridine</topic><topic>interictal ataxia</topic><topic>SARA</topic><topic>video case report</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><note type="content"> This article includes supplementary video clips, available online at http://www.interscience.wiley.com/jpages/0885‐3185/suppmat .Supporting Info Item: Please see article for description of video. - </note><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><detail type="issue"><caption>no.</caption><number>9</number></detail><extent unit="pages"><start>1314</start><end>1316</end><total>4</total></extent></part></relatedItem><identifier type="istex">5A29F579CCD897BEF9D98809889B96228D2F0AFA</identifier><identifier type="DOI">10.1002/mds.22071</identifier><identifier type="ArticleID">MDS22071</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2008 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D56 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000D56 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:5A29F579CCD897BEF9D98809889B96228D2F0AFA
|texte= Potassium channel blocker 4‐aminopyridine is effective in interictal cerebellar symptoms in episodic ataxia type 2 — A video case report
}}
| This area was generated with Dilib version V0.6.23. |  |